FUNCTIONAL AREAS – Page 35

Excipient variability impact during early development – regulatory scrutiny implications

Identifying symptoms of excipient variability is essential for maintaining product quality and compliance. Common signals include:Click to read the full article.

Tech transfer readiness gaps during comparability assessment – CAPA during development lifecycle

Identifying the symptoms and signals of tech transfer readiness gaps during comparability assessments is crucial. To effectively monitor this, it is vital to recognize indicators that may suggest underlying issues.…

Excipient variability impact during transfer to manufacturing – how to ensure smooth tech transfer

Identifying early signs of excipient variability can prevent larger quality issues during the manufacturing process. Common symptoms include:Click to read the full article.

Design space poorly justified during pilot scale – downstream GMP risk and prevention

Recognizing early symptoms that indicate a poorly justified design space is crucial for maintaining compliance. Symptoms may manifest in several forms:Click to read the full article.

Process knowledge not captured during transfer to manufacturing – downstream GMP risk and prevention

Identifying early signals of unrecorded process knowledge is essential to preventing more significant quality issues. Symptoms may include:Click to read the full article.

Design space poorly justified during scale-up – data package improvements for filing

Identifying symptoms that indicate a poorly justified design space is crucial for timely intervention. Some common signals that may arise include:Click to read the full article.

Design space poorly justified during pilot scale – CAPA during development lifecycle

Identifying symptoms that indicate problems with design space justification is crucial for early intervention. Common symptoms include:Click to read the full article.

Tech transfer readiness gaps during pilot scale – CAPA during development lifecycle

Tech transfer readiness gaps frequently manifest as a variation in product quality or inconsistencies in batch performance. Below are common symptoms that may indicate potential readiness issues:Click to read the…

Method development instability during scale-up – data package improvements for filing

The initial indication of method development instability during scale-up may manifest as unexpected variability in analytical results. Key symptoms include:Click to read the full article.

Process knowledge not captured during pilot scale – regulatory scrutiny implications

Implications of Uncaptured Process Knowledge During Pilot Scale for Regulatory Compliance In the competitive pharmaceutical landscape, maintaining stringent adherence to regulatory standards is paramount. A common pitfall occurs when critical…

Scale-up risk not identified during comparability assessment – regulatory scrutiny implications

Recognizing the early signs of scale-up risks is crucial in averting more extensive issues later in the manufacturing process. Symptoms often observed include changes in product quality, variations in yield,…

Scale-up risk not identified during scale-up – regulatory scrutiny implications

Recognizing the symptoms of potential scale-up risks is critical to preemptively address deviations before they escalate into significant quality issues. Symptoms can manifest at various stages in the manufacturing life…